Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer -

Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer
Information type: Other primary research
Source: British Journal of Clinical Pharmacology
Specialities: Cancers
Summary
This analysis from data from 15 studies (n=779) found that the pharmacokinetics of lenvatinib were unaffected by pH-elevating agents, dose, age, sex, race, alanine aminotransferase, aspartate aminotransferase or bilirubin levels, or renal function.
UKMi comment
Lenvatinib is a multiple receptor tyrosine kinase inhibitor. It is currently licensed for use in thyroid cancer radioiodine-refractory differentiated cancer, and also under investigation for use in renal cell carcinoma and hepatocellular carcinoma.
Related links: